Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events.
Across the three collaborations, Tentarix will receive upfront payments and an equity investment from Gilead totaling USD 66m.
In addition, Gilead has the option to acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for USD 80m per subsidiary.
Beginning in the first quarter of 2022, consistent with recent industry communications from the US Securities and Exchange Commission, Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures.
The companies expect the transaction with Tentarix to reduce Gilead's GAAP and non-GAAP 2023 EPS by approximately USD 0.03 – USD 0.04.
Tentarix's mission is to develop first-in-class, targeted, multifunctional, conditional therapies. The company is focused on modalities that have cell specific function and has built a team that aims to transform biologics.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss